Acute Myeloid Leukemia
Conditions
Interventions
Low risk group/mediun-to-high risk group:Lisaftoclax combined with Ara-C and Idarubicin
Sponsors
The First Affiliated Hospital of Wenzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Voluntarily sign the informed consent form; 2.Age >= 18 years; 3.Adequate hepatic and renal function: Serum bilirubin =50%, New York Heart Association functional classification NYHA I/II); 5.Performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG) scale; 6.Non-pregnant and non-lactating women; 7.For all women of childbearing potential, a negative pregnancy test (hCG) is required to rule out pregnancy; 8.For all men of childbearing potential, contraception must be used during treatment with lissatoclax and for 3 months after the last dose.
Exclusion criteria
Exclusion criteria: 1. Allergy or contraindication to any drug involved in the regimen; 2. Liver and kidney functions are significantly abnormal, exceeding the inclusion and exclusion criteria; 3. Heart disease: including echocardiographic EF 2), ECG QTc >470 ms; 4. Pulmonary disease: pulmonary edema, pleural effusion (CTCAE score >2); 5. Participation in other clinical studies at the same time.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Minimal residual disease negative rate;Cumulative recurrence rate;Event-free survival;Overall survival rate; | — |
Countries
China
Contacts
Public ContactSongfu Jiang
The First Affiliated Hospital of Wenzhou Medical University
Outcome results
None listed